Barbara D. Wamil - Concepedia

Author

Barbara D. Wamil

Vanderbilt University

Also Known As

B D Wamil, B Wamil, B. D. Wamil, B. Wamil, Barbara D Wamil, Barbara D. Wamil, Barbara Wamil

Publications

458

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University

About

Barbara D. Wamil is an author at Vanderbilt University specializing in medicine, immunology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	250
2	Immunology	5	5	101
3	Health Sciences	1	1	120
4	Cell Biology	1	1	14
5	Microbiology	1	1	16

Barbara D. Wamil

Publications

429

Citations

H-Index

Page 1

	Year	Citations
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial Ian Smith, Denise A. Yardley, Howard A. Burris, Journal of Clinical Oncology Breast OncologyGynecologyPharmacotherapyDfs EventsOncology	2017	120
Teriflunomide added to interferon-β in relapsing multiple sclerosis M. S. Freedman, Jerry S. Wolinsky, Barbara D. Wamil, Neurology	2012	78
CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury Artur W. Wamil, Barbara D. Wamil, Carl G. Hellerqvist Proceedings of the National Academy of Sciences	1998	57
Phase I study of the antineovascularization drug CM101. Russell F. DeVore, Carl G. Hellerqvist, GAIL WAKEFIELD, PubMed Bacterial PolysaccharideImmunologyPathologyPharmacotherapyImmunotherapeutics	1997	41
Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial Barbara D. Wamil, Gary B. Thurman, Håkan Sundell, Journal of Cancer Research and Clinical Oncology Soluble E-selectinTumor-inhibiting Anti-neovascularization AgentMedicinePharmacologyPathology	1997	29
CM101 stimulates cutaneous wound healing through an anti-angiogenic mechanism Lillian B. Nanney, Barbara D. Wamil, Jeffrey S. Whitsitt, Angiogenesis	2001	20
Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin) Gary B. Thurman, David L. Page, Barbara D. Wamil, Journal of Cancer Research and Clinical Oncology InflammationImmunotoxicologyImmunologyExperimental PathologyGbs Toxin	1996	17
Isolation and identification of the group B streptococcal toxin CM101 from infants with sepsis Håkan Sundell, Heping Yan, Clint E. Carter, The Journal of Pediatrics Microbial ToxinMedical MicrobiologyPathogenesisImmunologySepsis	2000	16
Functional studies on the anti-pathoangiogenic properties of CM101 Heping Yan, Clint E. Carter, Enze Wang, Angiogenesis Functional StudiesMetalloproteinMolecular Biology	1998	14
Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. C Fu, S. Bardhan, N D Cetateanu, PubMed Therapeutic PotentialMicrobial PathogensImmunologyPathologyImmunologic Mechanism	2001	14

Page 1